Anesthetic Management of Three Parturients With von Willebrand Disease

Von Willebrand Hastalığı Olan Üç Gebenin Anestezi Yönetimi

ABSTRACT

Von Willebrand Disease (vWD) cases with bleeding symptoms can be admitted repetitively and anesthesia is required for minor or major surgery. We aimed to present anesthetic management of three patients with vWD and their post-operative follow up by discussing it in accordance with the literature. Any patient with vWD scheduled for surgery and/or delivery needs careful antenatal evaluation and long lasting postpartum follow up in a tertiary care center by multidisciplinary approach where blood and/or factor concentrates readily available.

Keywords: von Willebrand Disease, surgery; cesarean or delivery

INTRODUCTION

Von Willebrand disease (vWD) is the most common hereditary bleeding disorder with a prevalence of 0.6-1.3% (1). Defective platelet adhesion and aggregation are the main characteristics of the disease. Patients with vWD presents mucosa-associated bleeding after surgery and trauma. Personal or family history of abnormal bleeding is related to decreased von Willebrand factor (vWF) and/or factor VIII (FVIII) (2). Administration of exogenous vWF concentrate or desmopressin (DDVAP) are used to increase the level of vWF levels. Due to the physiologic changes of pregnancy in coagulation, FVIII and vWF levels can reach as high as 250% particularly near term, and rapidly decreases following delivery to return baseline in 6 weeks. So pregnant women need careful preoperative evaluation and follow up (3). We aimed to share our anesthetic management of three patients with vWD.

Case report: Informed consents were obtained from patients.

Case 1: a 24 year-old term parturient with previous abortus imminens history underwent cesarean section (CS). Patient’s laboratory results were presented in Table I. Patient received preoperatively vWF/factor VIII concentrate of 40 IU kg⁻¹ and had CS under general anesthesia, with intravenous (IV) propofol 2 mg kg⁻¹ + 100 µg fentanyl + 0.5 mg kg⁻¹ rocuronium followed by intubation with 7.0 mm
cuffed tube, and anesthesia was maintained with sevoflurane 1 MAC in 50% oxygen-air mixture. Extubation was performed using sugammadex IV 2 mg kg\(^{-1}\). Postpartum period was uneventful without any hemorrhage.

**Case 2;** A 33 year-old woman had spontaneous vaginal birth with IV infusion of vWF/F VIII concentrate 40 IU kg\(^{-1}\). Patient was admitted on the postpartum 13\(^{th}\) day because of abnormal vaginal bleeding and epistaxis. She was treated with 3000 IU vWF/F VIII C, tranexamic acid (TXA) 4x1 gram (g), three units (U) of RBC (red blood cell) due to ongoing bleeding with Hb: 7 g dL\(^{-1}\). One week later the patient was re-admitted to the ICU due to vaginal bleeding. She received 3000 IU vWF/FVIII, TXA 4x1 g, methyl-ergonovine 0.125 mg and 1 U of RBC transfusion (meanwhile Hb 7.3 was g dL\(^{-1}\)) and discharged after 6 days. She was prescribed oral contraceptive (ethinyl estradiol 30 mcg + desogestrel 150 mcg 2x1). Four years later due to abnormal vaginal bleeding, cervical cauterisation was performed along with infusing vWF/factor VIII (2x2000 U of vWF/F VIII concentrate). Based on the pathological report revealing high grade squamous intraepithelial lesion, abdominal hysterectomy was planned under general anesthesia. Since her factor levels were very low (Table I), she received preoperatively 2x4000 of vWF/F VIII concentrate and followed by 3 U of RBC and FFP transfusion intraoperatively because of ongoing bleeding. Patient was discharged to the ward and no complication was observed in the short-term hospital follow-up. However, after three weeks patient was re-admitted because of vaginal cuff bleeding again. She was treated with 3000 U of vWF/F VIII concentrate followed up in ICU and was discharged with oral contraceptive and TXA prescription.

**Case 3;** A 29 year-old term parturient with vWD, was admitted for CS after hematology referral. Patient’s factor levels at the end of the pregnancy were within normal range (Table I). She underwent general anesthesia using thiopentone and succinylcholine (intubation with 7.0 mm cuffed tube) and anesthesia maintained with sevoflurane in 50% oxygen-air mixture. After delivery, uterotonics (oxytocine and carbetocine) and TXA were given intravenously. Intravenous paracetamol 1 g and morphine with PCA were administered for postoperative analgesia. Perioperative period and extubation was uneventful without need for any blood or factor transfusion.

**DISCUSSION**

In this case report, successful management of 3 patients with vWD (two of them had CS under general anesthesia and one had spontaneous vaginal birth) was presented.

Von Willebrand factor is multimeric plasma glycoprotein produced by megakaryocytes and endothelial cells which is crucial for hemostasis. The vWF, which is a carrier glycoprotein for FVIII (secondary hemostasis), mediates the attachment of platelets to the damaged endothelium (primary hemostasis)\(^4\). According to the current classification, vWD has three main types (Table II)\(^5\). Type 1 has partial deficiency of the factor and responsible for 70% of cases of normal vWF, quantitative reduction (reduced vWF antigen and cofactor) but the multimers are normal, and Factor VIII is proportionally reduced but not as much as vWF\(^6\). FVIII and vWF levels increase and reach the normal value in most pregnant women with type 1\(^4\). In type 2, there is a qualitative defect in vWF, quantitative reduction (reduced vWF antigen and cofactor) but the multimers are normal, and Factor VIII is proportionally reduced but not as much as vWF\(^6\). FVIII and vWF levels increase and reach the normal value in most pregnant women with type 1\(^4\). Type 3 is the most rare and severe form of vWD manifest with complete absence of vWF. FVIII and vWF levels never increase in pregnant women with VWD and needs strict follow up of bleeding and its treatment. Both type 2 and 3 patients should be managed by a multidisciplinary team at a tertiary center because

**Table I. Laboratory results**

<table>
<thead>
<tr>
<th>Case 1 (type 1)</th>
<th>Case 2 (type 2)</th>
<th>Case 3 (unknown type)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVIII (%)</td>
<td>vWF antigen (%)</td>
<td>vWF/ristocetin cofactor (%)</td>
</tr>
<tr>
<td>47</td>
<td>30</td>
<td>32</td>
</tr>
<tr>
<td>1.2</td>
<td>3.2</td>
<td>1.7</td>
</tr>
<tr>
<td>97</td>
<td>104</td>
<td>150</td>
</tr>
</tbody>
</table>

Normal reference: 50-100%

**Table II. Classification of vWD and bleeding tendency**

<table>
<thead>
<tr>
<th>Type</th>
<th>Pathology</th>
<th>Bleeding tendency</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Quantitative decrease in vWF</td>
<td>Mild</td>
</tr>
<tr>
<td>2A</td>
<td>Qualitative decrease in vWF</td>
<td>Mild-moderate</td>
</tr>
<tr>
<td>2B</td>
<td>Qualitative decrease in vWF and mild thrombocytopenia</td>
<td>Mild-moderate</td>
</tr>
<tr>
<td>3</td>
<td>Complete absence of vWF</td>
<td>Severe</td>
</tr>
</tbody>
</table>
of mild-moderate to severe bleeding tendency. If the baseline levels of both vWF and FVIII >30 U dL⁻¹, it will probably reach normal at the end of pregnancy. Thus, specific anti-hemorrhagic prophylaxis is rarely needed (7).

In a recent retrospective analysis of 106 deliveries among 71 individual vWD patients at a large tertiary-care center, there were 54 vWD type 1, 6 vWD type 2, and 11 vWD type unknown. Forty-three cases (40.6%) underwent cesarean deliveries and neuraxial techniques were performed in 94 out of all 106 deliveries (88.7%). Treatment with DDAVP or vWF/factor VIII concentrate before neuraxial anesthesia was used in 27 out of 94 of parturients (28.7%). Eleven deliveries (10.4%) were complicated by postpartum hemorrhage with an estimated blood loss of ≥1000 mL. No adverse anesthetic outcomes including neuraxial hematoma or thromboembolic events were noted. This suggests that neuraxial anesthesia/analgesia can be safely performed with multidisciplinary appropriate pretreatment based on the type and severity of vWD (8). In patients with type 2 disease, neuraxial block may be considered if the vWF and factor VIII levels are normal but it should be avoided in patients with type 3 disease (9). Our management for vWD varied case by case on the basis of predelivery factor levels. In our first case, since preoperative factor levels were lower than normal reference limits, she underwent CS under general anesthesia after she was given vWF/F VIII concentrate. In the second case factor levels were extremely low, she had vaginal birth and received vWF/F VIII concentrate replacement and discharged. However, she had postpartum bleeding twice requiring admission to hospital to treat with vWF/F VIII concentrate and transfusion. Eventually, she underwent total abdominal hysterectomy under general anesthesia via multidisciplinary approach and treatment. Our third patient’s type was unknown but both factor levels at the end of the pregnancy was totally normal and factor replacement therapy wasn’t given preoperatively. We didn’t observe any bleeding after surgery and postpartum period without need for factor replacement as we expected. None of our cases had thrombocytopenia.

According to the specific perioperative management recommendations; DDAVP is first line treatment for minor bleeding surgery, replacement of vWF with plasma derived products for major bleeding surgery and antifibrinolytic drugs as hemostatic adjuncts (10). Based on these three cases (type 1, 2 and unknown vWD), preoperative factor level determination and medical bleeding history guided us for preoperative factor replacement therapy and peroperative transfusion requirement.

In conclusion vWD parturients with bleeding symptoms can be admitted repetitively, therefore any parturient with vWD scheduled for surgery and/or delivery needs careful antenatal evaluation and postpartum follow up in tertiary care centers by multidisciplinary approach where blood and/or factor concentrates readily available.

Conflict of Interest: None
Informed Consent: Obtained

REFERENCES